<DOC>
	<DOCNO>NCT02686658</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy intravitreous administration Zimura® administer subject geographic atrophy ( GA ) secondary dry age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>A Phase 2/3 Trial Assess Safety Efficacy Intravitreous Administration Zimura® ( Anti-C5 Aptamer ) Subjects With Geographic Atrophy Secondary Dry Age-Related Macular Degeneration</brief_title>
	<detailed_description>Approximately 300 subject randomize 1:1:1 ratio follow dose group : - Zimura® Dose 1 - Zimura® Dose 2 - Sham Subjects receive monthly intravitreal injection Zimura® Sham 24 month . An interim analysis conduct , follow , study may expand include subject .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Subjects either gender age ≥ 50 year Diagnosis Nonfoveal GA secondary dry AMD Retinal atrophy involve fovea Evidence Choroidal Neovascularization ( CNV ) Any prior treatment AMD prior intravitreal treatment indication either eye , except oral supplement vitamin mineral Any intraocular surgery thermal laser within three ( 3 ) month trial entry Any prior thermal laser macular region , regardless indication Any ocular periocular infection twelve ( 12 ) week prior entry Previous therapeutic radiation region study eye Any sign diabetic retinopathy either eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Geographic Atrophy</keyword>
	<keyword>Dry age-related macular degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Zimura®</keyword>
	<keyword>Anti-inflammatory</keyword>
	<keyword>Complement C5 inhibition</keyword>
</DOC>